NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Rallybio Corporation (RLYB) Stock Analysis

Rallybio Corporation (RLYB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RLYB

$16.93

+$0.05 (+0.30%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RLYB with… →

RLYB Key Statistics

As of Sep 4, 2026
Trading
Open
$16.75
Previous Close
$16.88
Day's Range
16.75–17.01
52-Week Range
3.67–17.57
Volume
4.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.85
Valuation
Market Cap
$89.88M
P/E Ratio
2.13
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
139.13
EPS (ttm)Profit attributable to each share over the last twelve months.
7.94
Financials (FY)
Revenue (FY)
$858.00K+34.91%
Net Income (FY)
−$8.98M
Profit marginThe share of revenue left as profit after all costs and taxes.
7051.24%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.31M
1-Year Return
+261.03%
Dividend and dates
Avg Volume
33.06K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RLYB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+208.40%
2025−28.54%
2024−59.83%
2023−63.62%
2022−31.13%
2021 (partial year)−32.34%

As of September 4, 2026.

RLYB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$858.00K−$8.98M−1046.4%
2024$636.00K−$57.78M−9084.1%
2023$0.00−$74.56M—
2022$0.00−$66.65M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$858.00K—−$33.06M−$8.98M−1046.4%
2024$636.00K—−$60.50M−$57.78M−9084.1%
2023$0.00—−$78.93M−$74.56M—
2022$0.00—−$67.88M−$66.65M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RLYB Valuation vs Biotechnology Median

Median of 656 stocks
MetricRLYBBiotechnology medianvs median
P/E2.1312.570.2x the median
P/S ratio139.1315.269.1x the median
Profit margin7051.24%0.00%7051.2 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Rallybio Corporation (RLYB) is capitalised at $89.88M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 7 employees.

RLYB last closed at $16.93 on September 4, 2026. That is +$0.05 (+0.30%) against the previous close. The 52-week range on file runs from $3.67 to $17.57. The latest close sits 361.17% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $858.00K. Against the prior fiscal year total of $636.00K, that is a change of +34.91%. The same year closed with a net loss of $8.98M. The reported profit margin is 7,051.24%. That is 7,051.2 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 7.94.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $858.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 2.13 times earnings. That is 0.2 times the Biotechnology median of 12.57. The price-to-sales ratio is 139.13. On price-to-sales that is 9.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +261.03%. Measured over 5 years, that is −31.57% a year compounded. The reported beta is −0.85. Annualized volatility over the trailing 5 years is 106.33%.

Growth & Income

No dividend is on file for RLYB.

So far in 2026 the price is +208.40%. Across the complete calendar years on file, 2025 returned −28.54% and 2023 returned −63.62%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Rallybio Corporation (RLYB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rallybio Corporation RLYB $89.88M 2.1
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Rallybio Corporation trades at a P/E of 2.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Visit website →